Eisai
4523.T
$44.12
Share price
0.76%
Change (1 day)
-33.12%
Change (1 year)
Categories
Eisai is a Japanese pharmaceutical company that is engaged in the R&D of drugs for the treatment of dementia and Alzheimer.
Revenue for Eisai (4523.T)
Revenue in 2024 (TTM): NZ$8.31 Billion
According to Eisai's latest financial reports the company's current revenue (TTM 
) is NZ$8.56 Billion. In 2023 the company made a revenue of NZ$8.36 Billion a decrease over the revenue in the year 2022 that were of NZ$8.74 Billion. The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.
Revenue history for Eisai from 2009 to 2024
Annual revenue
| Year | Revenue | Change |
|---|---|---|
| 2024 (TTM) | NZ$8.31 B | -0.6% |
| 2023 | NZ$8.36 B | -4.38% |
| 2022 | NZ$8.74 B | -6.07% |
| 2021 | NZ$9.31 B | 0.75% |
| 2020 | NZ$9.24 B | 2.66% |
| 2019 | NZ$9.00 B | 6.09% |
| 2018 | NZ$8.48 B | 18.79% |
| 2017 | NZ$7.14 B | 0.59% |
| 2016 | NZ$7.10 B | 3.62% |
| 2015 | NZ$6.85 B | 3.23% |
| 2014 | NZ$6.64 B | -8.07% |
| 2013 | NZ$7.22 B | -15.7% |
| 2012 | NZ$8.56 B | -19.68% |
| 2011 | NZ$10.66 B | -12.37% |
| 2010 | NZ$12.17 B | 5.84% |
| 2009 | NZ$11.50 B |